Literature DB >> 18600456

The D2/D3 agonist PD128907 (R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol) inhibits stimulated pyloric relaxation and spontaneous gastric emptying.

Purna Kashyap1, Maria-Adelaide Micci, Sarina Pasricha, Pankaj Jay Pasricha.   

Abstract

BACKGROUND: Enteric neuronal dopamine (DA) inhibits acetylcholine release and gastric motility; this has been thought to be mediated via neuronal dopamine-2 receptor (D2R). The aim of this study was to investigate the modulation of gastric motility by the dopamine-3 receptor (D3R).
METHODS: Adult Sprague-Dawley rats were used. Pyloric relaxation in response to electrical field stimulation (EFS) was assessed in an organ bath in the presence of varying concentrations of a selective D3R agonist, PD128907. Gastric emptying was assessed by the phenol red method after rats were treated with varying doses of PD128907 or DA with and without a selective D3R antagonist, L-nafadotride.
RESULTS: Immunoblotting and immunohistochemistry confirmed the presence of D3R in the myenteric neurons in the rat pylorus. D3R activation reduced EFS-induced relaxation of pyloric strips in a dose-dependent manner and significantly delayed gastric emptying compared with vehicle. The D3R antagonist partially reversed the effect of DA on gastric emptying.
CONCLUSIONS: Our data suggest a novel role for D3R in regulation of gastric motility. D3R activation delays gastric emptying, an effect that may be due to impairment of pyloric relaxation. D3R antagonists therefore hold promise as useful agents for treatment of gastric motility disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18600456     DOI: 10.1007/s10620-008-0335-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  In vivo occupancy of D2 dopamine receptors by nafadotride.

Authors:  B Levant; N R Vansell
Journal:  Neuropsychopharmacology       Date:  1997-08       Impact factor: 7.853

2.  Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.

Authors:  R K Sunahara; H C Guan; B F O'Dowd; P Seeman; L G Laurier; G Ng; S R George; J Torchia; H H Van Tol; H B Niznik
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

3.  Involvement of dopamine D3 receptors in the area postrema in R(+)-7-OH-DPAT-induced emesis in the ferret.

Authors:  T Yoshikawa; N Yoshida; K Hosoki
Journal:  Eur J Pharmacol       Date:  1996-04-22       Impact factor: 4.432

4.  A dopamine D3 receptor agonist, 7-OH-DPAT, causes vomiting in the dog.

Authors:  N Yoshida; T Yoshikawa; K Hosoki
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

5.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.

Authors:  H H Van Tol; J R Bunzow; H C Guan; R K Sunahara; P Seeman; H B Niznik; O Civelli
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

6.  Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through Galpha(qo5).

Authors:  Robert B Moreland; Masaki Nakane; Diana L Donnelly-Roberts; Loan N Miller; Renjie Chang; Marie E Uchic; Marc A Terranova; Earl J Gubbins; Rosalind J Helfrich; Marian T Namovic; Odile F El-Kouhen; Jeffrey N Masters; Jorge D Brioni
Journal:  Biochem Pharmacol       Date:  2004-08-15       Impact factor: 5.858

Review 7.  Domperidone: review of pharmacology and clinical applications in gastroenterology.

Authors:  Savio C Reddymasu; Irfan Soykan; Richard W McCallum
Journal:  Am J Gastroenterol       Date:  2007-05-03       Impact factor: 10.864

Review 8.  Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics.

Authors:  M Tonini; L Cipollina; E Poluzzi; F Crema; G R Corazza; F De Ponti
Journal:  Aliment Pharmacol Ther       Date:  2004-02-15       Impact factor: 8.171

9.  Enteric dopaminergic neurons: definition, developmental lineage, and effects of extrinsic denervation.

Authors:  Z S Li; T D Pham; H Tamir; J J Chen; M D Gershon
Journal:  J Neurosci       Date:  2004-02-11       Impact factor: 6.167

10.  Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice.

Authors:  Zhi Shan Li; Claudia Schmauss; Abigail Cuenca; Elyanne Ratcliffe; Michael D Gershon
Journal:  J Neurosci       Date:  2006-03-08       Impact factor: 6.167

View more
  7 in total

Review 1.  Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years.

Authors:  Purna Kashyap; Gianrico Farrugia
Journal:  Gut       Date:  2010-09-25       Impact factor: 23.059

2.  Ghrelin prevents levodopa-induced inhibition of gastric emptying and increases circulating levodopa in fasted rats.

Authors:  L Wang; N P Murphy; A Stengel; M Goebel-Stengel; D H St Pierre; N T Maidment; Y Taché
Journal:  Neurogastroenterol Motil       Date:  2012-03-23       Impact factor: 3.598

3.  Preventive effect of rikkunshito on gastric motor function inhibited by L-dopa in rats.

Authors:  Lixin Wang; Sachiko Mogami; Hiroshi Karasawa; Chihiro Yamada; Seiichi Yakabi; Koji Yakabi; Tomohisa Hattori; Yvette Taché
Journal:  Peptides       Date:  2014-03-11       Impact factor: 3.750

Review 4.  Choosing an Animal Model for the Study of Functional Dyspepsia.

Authors:  Yang Ye; Xue-Rui Wang; Yang Zheng; Jing-Wen Yang; Na-Na Yang; Guang-Xia Shi; Cun-Zhi Liu
Journal:  Can J Gastroenterol Hepatol       Date:  2018-02-12

5.  Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis.

Authors:  Laura Kreckler; Mark Osinski; Scott Williams; Roger Whiting
Journal:  J Exp Pharmacol       Date:  2022-02-09

6.  Usefulness of a Kampo Medicine on Stress-Induced Delayed Gastric Emptying in Mice.

Authors:  Sachiko Mogami; Ryutaro Arita; Miwa Nahata; Naoki Fujitsuka; Shin Takayama; Tadashi Ishii
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-31       Impact factor: 2.629

7.  Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor.

Authors:  Chunlin Chen; Wenwen Zhang; Muhammad Bari; Cristina Almansa; Mike Baratta; Maria Rosario
Journal:  Clin Pharmacol       Date:  2021-07-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.